mTOR kinase inhibitors as potential cancer therapeutic drugs.
mTOR kinase inhibitors as potential cancer therapeutic drugs.
复制标题
DOI:
10.1016/j.canlet.2013.06.017
复制
发表时间:
2013-10-28
期刊:
影响因子:
9.7
通讯作者:
Sun, Shi-Yong
中科院分区:
文献类型:
--
作者:
Sun, Shi-Yong
The mammalian target of rapamycin (mTOR) plays a critical role in the positive regulation of cell growth and survival primarily through direct interaction with raptor (forming mTORC complex 1; mTORC1) or rictor (forming mTOR complex 2; mTORC2). The mTOR axis is often activated in many types of cancer and thus has become an attractive cancer therapeutic target. The modest clinical anticancer activity of conventional mTOR allosteric inhibitors, rapamycin and its analogues (rapalogs), which preferentially inhibit mTORC1, in most types of cancer, has encouraged great efforts to develop mTOR kinase inhibitors (TORKinibs) that inhibit both mTORC1 and mTORC2, in the hope of developing a novel generation of mTOR inhibitors with better therapeutic efficacy than rapalogs. Several TORKinibs have been developed and actively studied preclinically and clinically. This review will highlight recent advances in the development and research of TORKinibs and discuss some potential issues or challenges in this area.
登录
查看更多内容
影响因子:
11.2
作者:
Holt, Sarah V.;Logie, Armelle;Smith, Paul D.
通讯作者:
Smith, Paul D.
影响因子:
11.5
作者:
Abraham, Robert T.;Gibbons, James J.
通讯作者:
Gibbons, James J.
影响因子:
7.3
作者:
Guertin, David A.;Sabatini, David M.
通讯作者:
Sabatini, David M.
影响因子:
5.7
作者:
Bhagwat, Shripad V.;Gokhale, Prafulla C.;Pachter, Jonathan A.
通讯作者:
Pachter, Jonathan A.
DOI:
10.1158/1078-0432.ccr-10-2285
发表时间:
2011-07-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Altman JK;Sassano A;Kaur S;Glaser H;Kroczynska B;Redig AJ;Russo S;Barr S;Platanias LC
通讯作者:
Platanias LC